Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
Rosen said it makes a big difference how a product is classified and which FDA office reviews it. “People would love products, for example, to be medical devices when they possibly can because it’s a lot less expensive and the time frame is generally a lot shorter,” he said.
He also said one proposed change – which would clarify that only product sponsors (such as drug companies or device makers) can submit a request for designation to suggest how a product should be classified and which office should be assigned to review it – is likely to be challenged because sponsors don’t always want to be identified early in the development process. “They want to keep things confidential so they engage us lawyers to write these requests without definitely identifying who they are,” he said.
Subscription required.
Rosen said it makes a big difference how a product is classified and which FDA office reviews it. “People would love products, for example, to be medical devices when they possibly can because it’s a lot less expensive and the time frame is generally a lot shorter,” he said.
He also said one proposed change – which would clarify that only product sponsors (such as drug companies or device makers) can submit a request for designation to suggest how a product should be classified and which office should be assigned to review it – is likely to be challenged because sponsors don’t always want to be identified early in the development process. “They want to keep things confidential so they engage us lawyers to write these requests without definitely identifying who they are,” he said.
Subscription required.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.